Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease
Atherosclerosis is the leading cause of death worldwide, especially in patients with type 2 diabetes mellitus (T2D). GLP-1 receptor agonists and DPP-4 inhibitors were demonstrated to play a markedly protective role for the cardiovascular system beyond their glycemic control. Several cardiovascular o...
Saved in:
Main Authors: | Federico Bernardini (Author), Annunziata Nusca (Author), Federica Coletti (Author), Ylenia La Porta (Author), Mariagrazia Piscione (Author), Francesca Vespasiano (Author), Fabio Mangiacapra (Author), Elisabetta Ricottini (Author), Rosetta Melfi (Author), Ilaria Cavallari (Author), Gian Paolo Ussia (Author), Francesco Grigioni (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease
by: Annunziata Nusca, et al.
Published: (2021) -
Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review
by: Teodor Salmen, et al.
Published: (2024) -
Tirzepatide - a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023) -
Uncertainties around incretin-based therapies: A literature review
by: Bader Al Tulaihi, et al.
Published: (2017) -
Non Incretin Effects of DPP-4 Inhibitors: Comparative Study
by: A Shabbir Ali Bhatti, et al.
Published: (2019)